Vergleich einer Therapie nach ATP-TCA (durchgezogene Linie)
mit einer herkömmlichen Therapie (gestrichelte Linie).
(Quelle: siehe Kurbacher CM, Cree IA, Bruckner HW, et al.*)

Andreotti PE, Cree IA, Kurbacher CM, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma, Cancer Res (1995) 55: 5276-5282.

Cree IA, Kurbacher CM, Untch M, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs (1996) 7:630-635.

Kurbacher CM, Bruckner HW, Cree IA, et al. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin Cancer Res (1997) 3:1527-1533.

Kurbacher CM, Cree IA, Bruckner HW, et al. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anti-Cancer Drugs (1998) 9:51-57. *

Konecny G, Crohns C, Pegram M, et al. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol (2000) 77:258-263.

Sharma S, Neale MH, DiNicolantonio F, et al. Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pretreated recurrent ovarian carcinoma. BMC Cancer (2003) 3:19.

Reinhold U, Hauschild A. Diagnostische Wertigkeit von Tumormarkeruntersuchungen und Verfahren zur prätherapeutischen Chemosensitivitätstestung, Der Onkologe (2001) 7:53-60.

Reinhold U, Tilgen W (Eds.) Chemosensitivity Testing in Oncology. Recent Results in Cancer Research 161 Springer Verlag Berlin, Heidelberg, New York, 2003.